Jazz Pharmaceuticals plc revenue by segment JAZZ

Annual Quarterly

Jazz Pharmaceuticals plc splits its revenue into 17 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Total Neuroscience at $2.9 billion, 67% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	4,718	4,268	4,069	3,834	3,659	3,094	2,364	2,162	1,891	1,619	1,488
Total Neuroscience	—	2,878 share 67.5%	—	2,708 share 70.6%	—	2,335 share 75.5%	—	—	—	—	—
Product And Services Product Sales Net Of Deductions	—	—	—	—	—	—	—	—	1,869 +16.7% share 98.9%	1,601 share 98.9%	—
Total Oxybate	—	—	—	—	—	1,801 share 58.2%	—	1,643 share 76.0%	—	—	—
Oncology	—	1,129 +1.6% share 26.5%	1,111 +9.5% share 27.3%	1,015 +16.2% share 26.5%	874 share 23.9%	—	554 +17.5% share 23.5%	472 share 21.8%	—	—	—
Epidiolex Epidyolex	—	—	972 +15.0% share 23.9%	845 +14.8% share 22.1%	736 share 20.1%	—	—	—	—	—	—
Xywav	—	—	—	—	958 +79.0% share 26.2%	535 +3406.9% share 17.3%	15 share 0.6%	—	—	—	—
Rylaze Enrylaze	—	—	411 +4.2% share 10.1%	394 share 10.3%	—	—	—	—	—	—	—
Zepzelca	—	—	320 +10.6% share 7.9%	290 +7.3% share 7.6%	270 +9.4% share 7.4%	247 +173.1% share 8.0%	90 share 3.8%	—	—	—	—
Defitelio Defibrotide	—	199 -7.9% share 4.7%	217 +17.7% share 5.3%	184 -5.3% share 4.8%	194 -1.8% share 5.3%	198 +1.1% share 6.4%	196 +13.2% share 8.3%	173 +15.7% share 8.0%	149 +11.8% share 7.9%	134 share 8.3%	—
Xyrem	—	146 -37.5% share 3.4%	234 share 5.7%	—	1,020 share 27.9%	—	1,742 +6.0% share 73.7%	1,643 +16.9% share 76.0%	1,405 +18.4% share 74.3%	1,187 share 73.3%	—
Erwinaze And Erwinase	—	—	—	—	—	69 -52.8% share 2.2%	147 share 6.2%	—	175 -11.5% share 9.2%	197 share 12.2%	—
Other Royalties And Contract Revenue	—	34 share 0.8%	—	21 +18.9% share 0.6%	18 +17.8% share 0.5%	15 share 0.5%	—	—	—	—	—
Sunosi	—	—	—	—	29 -50.2% share 0.8%	58 +104.4% share 1.9%	28 +662.9% share 1.2%	4 share 0.2%	—	—	—
Ziihera	—	25 +2260.6% share 0.6%	1 share 0.0%	—	—	—	—	—	—	—	—
Product And Services Royalties And Contract Revenue	—	—	—	—	18 +17.8% share 0.5%	15 -9.9% share 0.5%	17 -35.4% share 0.7%	26 +22.0% share 1.2%	21 +24.0% share 1.1%	17 share 1.1%	—
Sativex	—	16 -13.8% share 0.4%	19 -4.0% share 0.5%	20 +16.9% share 0.5%	17 +32.4% share 0.5%	13 share 0.4%	—	—	—	—	—
Other Products	—	14 +23.5% share 0.3%	11 -17.2% share 0.3%	14 +108.4% share 0.4%	7 -32.2% share 0.2%	10 +43.2% share 0.3%	7 -61.0% share 0.3%	18 -55.7% share 0.8%	40 -20.7% share 2.1%	50 share 3.1%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: JAZZ (Nasdaq)
Fiscal year ends: December 31
Incorporated in: Ireland
Headquarters: Dublin
SEC filer status: Large accelerated filer
SEC CIK: 1232524
Former names: JAZZ PHARMACEUTICALS INC (until Jan 18, 2012)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.